Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by Sarb99on Jan 04, 2021 8:29pm
277 Views
Post# 32221085

Medivolve needed an investor relation and funds to expand.

Medivolve needed an investor relation and funds to expand.
Stan Bharti is a shrewd businessman and the biggest investor before this private placement in QuestCap. I don't think Forbes and Manhattan could not raise another $5 million if needed. They won't let QuestCap issue 20 million shares to Cannacord without a good deal. 
 
Canaccord can bring a lot of investors for the revenue, Medivolve is supposed to be generating with 100 to 700 testing sites.  I think QuestCap management tried everything they couldn't manage Anonymous. These Anonymous held QSC share price down. The logic we were thinking was they knew, QuestCap is going to need funding at some point. QuestCap management issued all these updates, but the share price never moved. So no way they can raise money at higher prices. That is the reason we kept saying hire an investor relation. 
 
I think management did better. Canaccord can bring investors to the table, and they also paid for those shares. QuestCap raised needed funds to expand quickly. As per private placement price, QSC was trading .25 to .28 cents before Cannacoerd started buying.
 
I hate, private placements but the fact is they needed to do something. Otherwise, even with 35 testing sites, the QSC share price should have been much higher. 
<< Previous
Bullboard Posts
Next >>